Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22815923 | 0.85 | NOTUM (0.49) | NOTUMPDE3AAKR1C2AKR1C1KMO | |
| SCHEMBL30026351 | 0.84 | HSD17B10 (0.46) | HSD17B10GRIN2BTTRKMO | |
| SCHEMBL365685 | 0.84 | HSD17B10 (0.46) | HSD17B10GRIN2BTTRKMO | |
| SCHEMBL3026638 | 0.81 | EPHX2 (0.41) | MAOB | |
| SCHEMBL8778326 | 0.79 | MAOB (0.54) | HSD17B10MAOB | |
| SCHEMBL22815981 | 0.78 | RHEB (0.49) | GRIN2BAKR1C2AKR1C1 | |
| SCHEMBL4055218 | 0.78 | EPHX2 (0.42) | HSD17B10CA12CA2CA9CA14 | |
| SCHEMBL29890447 | 0.78 | EPHX2 (0.42) | HSD17B10CA12CA2CA9CA14 | |
| SCHEMBL8462016 | 0.78 | NOTUM (0.44) | NOTUMPDE3AEPHX1GRIN2BPGK1 | |
| SCHEMBL25798505 | 0.77 | PDE2A (0.40) | HSD17B10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12240855-B2 | Pyrrolopyrazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-3968994-B1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-113939290-A | ABHD12 inhibitors and methods of making and using the same | H.隆德贝克有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-1738794-B | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY | 2010-12-22 | — | — | CN | disclosed |
| EP-1565430-B1 | BIGUANIDE DERIVATIVES | JACOBUS PHARMA CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7563792-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7256218-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| CN-1738794-A | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY (US) | 2006-02-22 | — | — | CN | disclosed |
| EP-1565430-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL CO. INC. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005037839-A1 | NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | ENTOMED (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | HSD17B10 296/4885NOTUM 643/4885CA12 1470/4885 |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | HSD17B10 3294/4885NOTUM 3726/4885CA12 4793/4885 |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | QDPR, DHODH, GLMN | HSD17B10 2509/4885NOTUM 2570/4885CA12 2273/4885 |
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | HSD17B10 1478/4885NOTUM 1437/4885CA12 4349/4885 |
| US-12240855-B2 | Pyrrolopyrazole derivative | PTDSS1, PTDSS2, SMPD1 | HSD17B10 1478/4885NOTUM 1437/4885CA12 4349/4885 |
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | ABHD12, SAMHD1, ABHD11 | HSD17B10 814/4885NOTUM 2628/4885CA12 3764/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | HSD17B10 1297/4885NOTUM 3019/4885CA12 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.